Landmark Stem Cells Trial Yields Positive Results
The Phase I trial of HuCNS-SC (purified human neural stem cells) conducted at OHSU Doernbecher Children's Hospital included six children with advanced stages of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), often referred to as Batten disease.
Firm Manufacturing Human Blood
A small Cleveland company may be on the verge of a huge medical breakthrough - artificial human blood. The technique is known as blood pharming and relies upon the creation of an artificial replacement for human bone marrow.
Hybrid Hearts could Solve Transplant Shortage
"Decellularising" hearts, livers and other organs taken either from human cadavers or from larger animals such as pigs, and coating them in stem cells harvested from people, could lead to a virtually limitless supply of organs for transplantation.
New Weapon to Fight Twin Blood Condition
Auckland Hospital in New Zealand is using a laser fetoscope to operate on unborn twins with a blood condition called Twin to Twin Transfusion Syndrome.
Neural Ganglioside GD2 Identifies a Subpopulation of Mesenchymal Stem Cells in Umbilical Cord
Data demonstrate that the cells selected by GD2 are a subpopulation of MSCs with feature of primitive precursor cells and provide evidence that GD2 can be a cell surface marker suitable for the isolation and purification of UC-MSCs in early-passage culture. [Cell Physiol Biochem]
Five Cord Blood Transplant Centers in Spain Join Study
The Gamida Cell-Teva Joint Venture announced today that five prestigious cord blood transplantations centers in Spain, three in Barcelona and two in Valencia, have joined the ExCell study.
Biotech Firm Ends Its Offer for Talecris
CSL, an Australian biotechnology firm, said it ended its proposed $3.1 billion acquisition of the Talecris Biotherapeutics Holdings Corporation after the deal was blocked by the Federal Trade Commission.
